
PharmaCell to Finalize Purchase of Cell Therapy Production Facility
PharmaCell has finalized its purchase of the cell therapy production facility from TiGenix.
Following the acquisition, PharmaCell will continue to operate its Maastricht facility in addition to the site at Sittard-Geleen. The Maastricht facility offers non-GMP process development and GMP-production facilities for early- to mid-stage clinical trials in cell therapy. The Geleen facility will offer clients the opportunity to support late stage clinical trials and commercial production for the industry.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.